Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Calcium, Rosuvastatin
2. Crestor
3. Rosuvastatin
4. Zd 4522
5. Zd4522
1. 147098-20-2
2. Crestor
3. Rosuvastatin Hemicalcium
4. Fortius
5. Rostar
6. Rosuvastatin Calcium Salt
7. Rosuvastatin Calcium [usan]
8. Rozavel
9. Suvikan
10. Zd4522
11. S-4522
12. Zd 4522
13. Rosuvastatin (as Calcium)
14. Zd4522 (calcium Salt)
15. Zd4522 Calcium
16. Zd-4522 Calcium
17. 83mvu38m7q
18. Chebi:77249
19. Nsc-747274
20. Nsc-758930
21. Rosuvastatincalcium
22. Crestor (tn)
23. Calcium (3r,5s,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(n-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
24. Rovista
25. Zd 4522, Calcium Salt
26. Calcium;(e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
27. S 4522
28. Unii-83mvu38m7q
29. Provisacor
30. Shufutan
31. Ezallor
32. Zd 4522 Calcium
33. Rosuvastatin Calcium- Bio-x
34. Zd-4522 (calcium Salt)
35. Schembl150740
36. Schembl429217
37. Chembl1744447
38. Dtxsid9045928
39. Rosuvastatin Calcium (jan/usan)
40. Rosuvastatin Calcium [jan]
41. Azd-4522
42. Bcp04131
43. Rosuvastatin Calcium [mart.]
44. S2169
45. Rosuvastatin Calcium [usp-rs]
46. Rosuvastatin Calcium [who-dd]
47. Akos005145896
48. Akos017343682
49. Rosuvastatin Calcium Salt [mi]
50. Ccg-270606
51. Ks-1109
52. Nsc 747274
53. Nsc 758930
54. (s-((r*,s*-(e)))- 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) Amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic Acid, Calcium Salt (2:1)
55. (s-(r*,s*-(e)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic Acid, Calcium Salt (2:1)
56. 6-heptenoic Acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, Calcium Salt (2:1), (3r,5s,6e)
57. As-12488
58. Br164378
59. Rosuvastatin Calcium [orange Book]
60. Rosuvastatin Calcium [ep Monograph]
61. Rosuvastatin Calcium [usp Monograph]
62. Roszet Component Rosuvastatin Calcium
63. R0180
64. D01915
65. Rosuvastatin Calcium Component Of Roszet
66. Q-201685
67. Q27146836
68. (s-((r*,s*-(e)))- 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) Amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic Acid, Calcium Salt (2:1)
69. (s-(r*,s*-(e)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic Acid, Calcium Salt
70. 6-heptenoic Acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, Calcium Salt (2:1), (3r,5s,6e)-
71. Bis((e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)-pyrimide-5-yl)-(3r,5s)3,5-dihydroxylhept-6-enoic Acid) Calcium
72. Calcium Bis[(3r,5s,6e)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate]
73. Calcium(3r,5s,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(n-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
74. Monocalcium Bis((3r,5s,6e)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methanesulfonyl (methyl) Amino] Pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate)
1. Rosuvastatin
2. Crestor
3. X-plended
Molecular Weight | 1001.1 g/mol |
---|---|
Molecular Formula | C44H54CaF2N6O12S2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 18 |
Exact Mass | 1000.2835107 g/mol |
Monoisotopic Mass | 1000.2835107 g/mol |
Topological Polar Surface Area | 304 Ų |
Heavy Atom Count | 67 |
Formal Charge | 0 |
Complexity | 761 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 4 | |
---|---|
Drug Name | Crestor |
Drug Label | CRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhe... |
Active Ingredient | Rosuvastatin calcium |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Ipr |
2 of 4 | |
---|---|
Drug Name | Rosuvastatin calcium |
PubMed Health | Rosuvastatin (By mouth) |
Drug Classes | Antihyperlipidemic |
Drug Label | CRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhe... |
Active Ingredient | Rosuvastatin calcium |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Tentative Approval |
Company | Mylan Pharma; Apotex; Aurobindo Pharma; Sandoz; Sun Pharma Global; Par Pharm; Watson Labs; Glenmark Generics; Teva Pharms |
3 of 4 | |
---|---|
Drug Name | Crestor |
Drug Label | CRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhe... |
Active Ingredient | Rosuvastatin calcium |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Ipr |
4 of 4 | |
---|---|
Drug Name | Rosuvastatin calcium |
PubMed Health | Rosuvastatin (By mouth) |
Drug Classes | Antihyperlipidemic |
Drug Label | CRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhe... |
Active Ingredient | Rosuvastatin calcium |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Tentative Approval |
Company | Mylan Pharma; Apotex; Aurobindo Pharma; Sandoz; Sun Pharma Global; Par Pharm; Watson Labs; Glenmark Generics; Teva Pharms |
Homozygous Familial Hypercholesterolaemia, Prevention of cardiovascular events, Primary combined (mixed) dyslipidaemia, Primary hypercholesterolaemia
Anticholesteremic Agents
Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-11-17
Pay. Date : 2017-05-23
DMF Number : 31410
Submission : 2017-03-28
Status : Active
Type : II
Certificate Number : CEP 2015-090 - Rev 02
Issue Date : 2025-07-11
Type : Chemical
Substance Number : 2631
Status : Valid
Date of Issue : 2025-04-21
Valid Till : 2028-04-14
Written Confirmation Number : WC-0363
Address of the Firm :
Registrant Name : Daeshin Pharmaceutical Co., Ltd.
Registration Date : 2020-12-17
Registration Number : 20200707-209-J-677(1)
Manufacturer Name : Centrient Pharmaceuticals India Private Limited
Manufacturer Address : Bhai Mohan Singh Nagar, Toansa District SBS Nagar (Nawanshahr) Punjab 144 533, India
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-04-08
Pay. Date : 2015-09-25
DMF Number : 29190
Submission : 2015-12-03
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rosuvastatin Calcium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rosuvastatin Calcium manufacturer or Rosuvastatin Calcium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rosuvastatin Calcium manufacturer or Rosuvastatin Calcium supplier.
PharmaCompass also assists you with knowing the Rosuvastatin Calcium API Price utilized in the formulation of products. Rosuvastatin Calcium API Price is not always fixed or binding as the Rosuvastatin Calcium Price is obtained through a variety of data sources. The Rosuvastatin Calcium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AKOS005145896 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AKOS005145896, including repackagers and relabelers. The FDA regulates AKOS005145896 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AKOS005145896 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AKOS005145896 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A AKOS005145896 supplier is an individual or a company that provides AKOS005145896 active pharmaceutical ingredient (API) or AKOS005145896 finished formulations upon request. The AKOS005145896 suppliers may include AKOS005145896 API manufacturers, exporters, distributors and traders.
click here to find a list of AKOS005145896 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A AKOS005145896 DMF (Drug Master File) is a document detailing the whole manufacturing process of AKOS005145896 active pharmaceutical ingredient (API) in detail. Different forms of AKOS005145896 DMFs exist exist since differing nations have different regulations, such as AKOS005145896 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A AKOS005145896 DMF submitted to regulatory agencies in the US is known as a USDMF. AKOS005145896 USDMF includes data on AKOS005145896's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AKOS005145896 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of AKOS005145896 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The AKOS005145896 Drug Master File in Japan (AKOS005145896 JDMF) empowers AKOS005145896 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the AKOS005145896 JDMF during the approval evaluation for pharmaceutical products. At the time of AKOS005145896 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of AKOS005145896 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a AKOS005145896 Drug Master File in Korea (AKOS005145896 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AKOS005145896. The MFDS reviews the AKOS005145896 KDMF as part of the drug registration process and uses the information provided in the AKOS005145896 KDMF to evaluate the safety and efficacy of the drug.
After submitting a AKOS005145896 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AKOS005145896 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of AKOS005145896 suppliers with KDMF on PharmaCompass.
A AKOS005145896 CEP of the European Pharmacopoeia monograph is often referred to as a AKOS005145896 Certificate of Suitability (COS). The purpose of a AKOS005145896 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of AKOS005145896 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of AKOS005145896 to their clients by showing that a AKOS005145896 CEP has been issued for it. The manufacturer submits a AKOS005145896 CEP (COS) as part of the market authorization procedure, and it takes on the role of a AKOS005145896 CEP holder for the record. Additionally, the data presented in the AKOS005145896 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the AKOS005145896 DMF.
A AKOS005145896 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. AKOS005145896 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of AKOS005145896 suppliers with CEP (COS) on PharmaCompass.
A AKOS005145896 written confirmation (AKOS005145896 WC) is an official document issued by a regulatory agency to a AKOS005145896 manufacturer, verifying that the manufacturing facility of a AKOS005145896 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting AKOS005145896 APIs or AKOS005145896 finished pharmaceutical products to another nation, regulatory agencies frequently require a AKOS005145896 WC (written confirmation) as part of the regulatory process.
click here to find a list of AKOS005145896 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AKOS005145896 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AKOS005145896 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AKOS005145896 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AKOS005145896 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AKOS005145896 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AKOS005145896 suppliers with NDC on PharmaCompass.
AKOS005145896 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AKOS005145896 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AKOS005145896 GMP manufacturer or AKOS005145896 GMP API supplier for your needs.
A AKOS005145896 CoA (Certificate of Analysis) is a formal document that attests to AKOS005145896's compliance with AKOS005145896 specifications and serves as a tool for batch-level quality control.
AKOS005145896 CoA mostly includes findings from lab analyses of a specific batch. For each AKOS005145896 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AKOS005145896 may be tested according to a variety of international standards, such as European Pharmacopoeia (AKOS005145896 EP), AKOS005145896 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AKOS005145896 USP).